Mylan Ireland Ltd Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN IRELAND LTD, and when can generic versions of MYLAN IRELAND LTD drugs launch?
MYLAN IRELAND LTD has five approved drugs.
There are sixteen US patents protecting MYLAN IRELAND LTD drugs.
There are sixty-two patent family members on MYLAN IRELAND LTD drugs in thirty-one countries and one supplementary protection certificate in one country.
Summary for Mylan Ireland Ltd
| International Patents: | 62 |
| US Patents: | 16 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | INJECTABLE;INJECTION | 017808-002 | Mar 29, 1991 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 7,585,879 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-003 | May 28, 2004 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-001 | Dec 7, 2001 | 4,818,816 | See Plans and Pricing |
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | See Plans and Pricing |
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,733,569 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mylan Ireland Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 104444 | See Plans and Pricing |
| Malaysia | 144482 | See Plans and Pricing |
| Russian Federation | 2006135927 | See Plans and Pricing |
| Hong Kong | 1097537 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mylan Ireland Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0084999 | 2002C/012 | Belgium | See Plans and Pricing | PRODUCT NAME: FONDAPARINUX SODIQUE; REGISTRATION NO/DATE: EU/1/02/206/001 20020321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
